INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion to Present at the 2017 JMP Securities Life Sciences Conference
NEW HAVEN, Conn., June 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, June 20,
View HTML
Toggle Summary Achillion to Present at the Jefferies 2017 Global Healthcare Conference
NEW HAVEN, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the Achillion management team will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017, at 4:30 p.m.
View HTML
Toggle Summary Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
Robust balance sheet to support planned Phase 2 clinical development program for ACH-4471, Achillion's first small molecule factor D inhibitor, for the potential treatment of PNH and C3G
View HTML
Toggle Summary Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 42 nd Annual Health Care Conference on Thursday,
View HTML
Toggle Summary Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
Ongoing Janssen global Phase 2 program with JNJ-4178, (odalasvir, AL-335, and simeprevir) focused on treatment durations of six and eight weeks for HCV genotype 1, 2, 4, 5, and 6 patients
View HTML
Toggle Summary Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
NEW HAVEN, Conn., April 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.  (Nasdaq:ACHN) today announced initiation of patient dosing in a Phase 2 open-label study of ACH-4471, Achillion's first orally-administered, small molecule factor D inhibitor, for patients with paroxysmal
View HTML